VNU cancels IMS deal
This article was originally published in The Tan Sheet
Executive Summary
Dutch publishing company VNU has agreed to terminate the merger with IMS Health after nearly 50% of shareholders voiced opposition to the deal, the Haarlem, Netherlands-based firm announces Nov. 17. The deal would have needed approval from more than half of shareholders in order to go through, VNU explained. The company will pay a termination fee of $15 mil. to IMS due to the falling-through of the deal. VNU announced the $7 bil. merger plans in July, but vacillated on the acquisition during the week of Nov. 7 (1"The Tan Sheet" Nov. 14, 2005, In Brief)...
You may also be interested in...
IMS/VNU merger
VNU is considering amending or terminating its merger agreement with IMS Health, the company says Nov. 7. The two firms agreed to the $7 bil. merger in July and expected the deal to close in early 2006 (1"The Tan Sheet" July 18, 2003, p. 9). However, Netherlands-based VNU says "shareholders claiming to represent 48% of VNU's outstanding shares [said] they would not support the transaction under any circumstances." VNU is AC Nielsen's parent company and provides consumer, marketing and media information to the healthcare industry; IMS Health focuses primarily on Rx healthcare. "Various possible alternatives" have been discussed including the deal's revision, VNU says...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: